Autoplaque vs CT Cardiomegaly
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if you require detailed, AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This tool is ideal for clinicians focused on precise heart attack risk prediction and guiding treatment strategies based on the extent and characteristics of atherosclerotic disease within the coronary arteries.
View Autoplaque →Choose CT Cardiomegaly if…
Choose CT Cardiomegaly if your primary need is automated, quantitative assessment of overall heart size relative to the thoracic cavity from general CT chest images. This command-line software is best suited for efficiently screening for cardiomegaly by providing accurate cardiothoracic ratio measurements, serving as a quick indicator for potential cardiac enlargement.
View CT Cardiomegaly →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | CT Cardiomegaly |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | Docker Container (Ubuntu 20.04), command-line software |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AutoplaqueAutoplaque (Tool A) is described as workstation-based software running on Windows or Mac platforms, suggesting a graphical user interface for interactive use. In contrast, CT Cardiomegaly (Tool B) is a command-line software deployed in a Docker container, which typically requires more technical expertise and offers a less intuitive user experience for clinicians.
Clinical Value
AutoplaqueAutoplaque (Tool A) provides quantitative analysis of coronary plaques and luminal stenoses, directly aiding in heart attack risk prediction and treatment guidance, addressing a critical and complex clinical need. While CT Cardiomegaly (Tool B) offers automated cardiothoracic ratio measurement for cardiomegaly detection, Autoplaque's detailed plaque characterization offers a more advanced and potentially higher impact on patient management.
Pricing & Value
TieNeither Autoplaque (Tool A) nor CT Cardiomegaly (Tool B) disclose their pricing information in the provided specifications. Without transparent pricing details for either product, it is impossible to conduct a meaningful comparison of their value propositions.
Enterprise Readiness
CT CardiomegalyCT Cardiomegaly (Tool B) explicitly states it is HIPAA compliant and offers a Business Associate Agreement (BAA), which are crucial for enterprise deployment in healthcare. Its Docker container deployment also suggests better scalability and integration capabilities within existing IT infrastructures compared to Tool A's workstation-based approach, which lacks explicit HIPAA or BAA statements.
Innovation
AutoplaqueAutoplaque (Tool A) focuses on the complex and highly relevant area of quantitative analysis and characterization of coronary atherosclerotic plaque for heart attack risk prediction. This represents a more advanced and nuanced application of AI in cardiology compared to CT Cardiomegaly's (Tool B) automated measurement of the cardiothoracic ratio, which is a more established and straightforward diagnostic metric.
Support & Docs
CT CardiomegalyCT Cardiomegaly (Tool B), developed by Innolitics, a commercial entity, implies a more formalized support structure and documentation, including the offering of a BAA which suggests a direct vendor relationship for support. Autoplaque (Tool A), developed by an academic medical center, does not provide specific details on its support or documentation, which may indicate a less standardized or publicly accessible support model.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | CT Cardiomegaly |
|---|---|---|
| Name | Autoplaque | CT Cardiomegaly |
| Company | Cedars-Sinai Medical Center: AIM | Innolitics |
| Description | Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | Innolitics' CT Cardiomegaly is an FDA-cleared AI-powered command-line software that automatically measures cardiothoracic ratio from CT chest images, assisting physicians in cardiomegaly detection with quantitative data. |
| Key Features | AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Analysis of coronary anatomy and pathology from CT Angiographic images; Workstation-based post-processing application; Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician); Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views; Measurement of vessel diameter and area | Automatic cardiothoracic ratio measurement; Machine learning algorithms for segmentation; Segmentation of heart and thoracic cavity; Calculates linear and area-based cardiothoracic ratios; Outputs PDF and JSON reports; Command-line software tool; Non-adaptive machine learning using MONAI framework; Validated against manual measurements by board-certified radiologists |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and CT Cardiomegaly.